Market Overview

A Dilutive Offering In The Offing? Oppenheimer Downgrades Synergy Pharma

Share:
A Dilutive Offering In The Offing? Oppenheimer Downgrades Synergy Pharma

Synergy Pharmaceuticals Inc (NASDAQ: SGYP) announced an offering of 21 million shares of its common stock at $2.58 per share in November, and at least one Wall Street analyst said another dilutive offering is imminent.

The Analyst

Oppenheimer's Derek Archila downgraded Synergy Pharmaceuticals' stock rating from Outperform to Perform with no assigned price target.

The Thesis

Synergy's Trulance therapy for constipation is a differentiated product and is likely to gain traction in the market, Archila said in the downgrade note. (See the analyst's track record here.) 

At the same time, Synergy is unlikely to quality for a third and fourth tranch of funding from the health care-focused investment firm CRG, which previously offered non-dilutive financing to the company, according to Oppenheimer. 

As part of the financing deal with CRG, Synergy needs to hold at least $128 million in cash on Jan. 31, 2018 to quality for the next tranche of $100 million, the analyst said. But based on the analyst's spend estimates for Opex, there is "some risk to whether or not" the company will meet the $128-million cash target that looms in a few weeks.

Synery's cost-reduction program, which was detailed during the third-quarter conference call, is unlikely to be sufficient to generate enough savings to eliminate the need for an additional stock raise, the analyst said.

"While we could be wrong, another equity raise seems most logical, either alone or potentially in conjunction with an acquisition to add another product to sales reps' bag," Archila said. "Debt seems less likely, given the terms of the CRG deal though there is always the possibility of renegotiation. We view U.S. licensing/ partnership/royalty deals as less beneficial to equity holders."

Price Action

Shares of Synergy Pharmaceuticals were down 11.68 percent Friday afternoon at $2.15.

Related Links:

Attention Biotech Investors: Brace For These January PDUFA Events

Thoughts On Synergy Pharma's Valuation As Cantor Initiates At Overweight

Latest Ratings for SGYP

DateFirmActionFromTo
Oct 2018DowngradesBuyNeutral
Oct 2018DowngradesBuyHold
Jan 2018DowngradesOutperformPerform

View More Analyst Ratings for SGYP
View the Latest Analyst Ratings

Posted-In: Derek Archilla Oppenheimer pharmaAnalyst Color Downgrades Health Care Analyst Ratings General Best of Benzinga

 

Related Articles (SGYP)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
FTVMorgan StanleyMaintains70.0
ROKMorgan StanleyMaintains142.0
WWEFBN SecuritiesUpgrades100.0
SWNCapital One FinancialUpgrades
AEISCowen & Co.Downgrades57.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Alphabet, IUSG, Zayo: 'Fast Money Halftime Report' Final Picks

What Is Melvin Capital, And What Does It Want With Electronic Arts?